NovoRapid insulin, produced by Danish pharmaceutical company Novo Nordisk, is once again available in Georgia, ensuring access for children with type 1 diabetes, the Ministry of Health announced.
Patients may choose to return to their previous treatment regimen with NovoRapid or continue using its analogue, Apidra, manufactured by Sanofi Aventis. The ministry noted that those who have been using Apidra from the start may remain on their current therapy without any changes.
Health Minister Mikheil Sarjveladze said all necessary steps were taken to restore the supply as quickly as possible and stressed that communication with Novo Nordisk is ongoing to prevent similar disruptions in the future.
The ministry says the delay occurred due to manufacturing issues at Novo Nordisk’s plant, which temporarily halted deliveries. Despite this, officials emphasised that there was no insulin shortage in the country, as patients continued receiving Apidra, a therapeutic equivalent to NovoRapid.
